查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1578806

PDGFR 抑制劑市場：按適應症、藥物類型、給藥方法和最終用戶 - 2025-2030 年全球預測

PDGFR Inhibitor Market by Therapeutic Indication (Gastrointestinal Stromal Tumors, Glioblastoma, Leukemia), Drug Type (Combination Therapy, Monotherapy), Mode Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

PDGFR抑制劑市場2023年估值為32.1億美元，預計2024年將達34.3億美元，複合年成長率為5.21%，到2030年將達到45.9億美元。

PDGFR（血小板源性生長因子受體）抑制劑的範圍和定義涉及針對PDGFR訊號途徑。該途徑在細胞增殖、存活和遷移中發揮關鍵作用，為治療方法癌症和纖維化疾病等疾病提供了一條有前景的途徑。需要這些抑制劑是因為它們具有治療神經膠母細胞瘤、前列腺癌等惡性和皮膚纖維肉瘤原形瘤等罕見疾病的潛力。透過抑制訊號途徑，這些藥物抑制腫瘤生長和轉移，這是它們的主要用途。 PDGFR 抑制劑的最終用途廣泛應用於製藥和生物技術領域，以及在臨床試驗和治療環境中使用這些藥物的醫院和研究機構。

主要市場統計
基準年[2023] 32.1億美元
預測年份 [2024] 34.3億美元
預測年份 [2030] 45.9億美元
複合年成長率（%） 5.21%

根據市場洞察，成長的主要驅動力是腫瘤疾病盛行率的增加、研發投入的高額以及對新型癌症治療方法的迫切需求。個人化醫療的技術進步和趨勢將進一步推動市場擴張。新的商機在於聯合治療的開發和靶向抗藥性腫瘤基因組學。公司可以透過投資與生物技術公司的合作研究和策略聯盟來利用這些優勢。然而，嚴格的監管核准、高昂的開發成本和潛在的副作用構成了重大挑戰，限制了市場成長。此外，替代療法的競爭壓力和不斷成長的腫瘤抗藥性需要持續的技術創新。

為了促進創新和研究，探索分子機制和新型生物標記以提高 PDGFR 抑制劑的療效和安全性至關重要。市場開拓洞察揭示了開發具有低毒性和更高生物有效性度的高選擇性抑制劑的重點。市場競爭激烈，主要企業不斷透過策略合併、收購和聯盟來尋求優勢，以加強其產品線。在此動態下，PDGFR 抑制劑市場持續穩定成長，為那些巧妙駕馭市場複雜性並利用新興趨勢和未滿足的醫療需求的公司提供了巨大的成長機會。

市場動態：揭示快速發展的 PDGFR 抑制劑市場的關鍵市場洞察

PDGFR 抑制劑市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

波特五力：駕馭 PDGFR 抑制劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 PDGFR 抑制劑市場的外部影響

外部宏觀環境因素在塑造 PDGFR 抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解PDGFR抑制劑市場的競爭格局

PDGFR 抑制劑市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：PDGFR 抑制劑市場供應商的績效評估

FPNV定位矩陣是評估PDGFR抑制劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃 PDGFR 抑制劑市場的成功之路

PDGFR 抑制劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料以及對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • PDGFR抑制劑應用的廣泛研發拓展了臨床應用
      • 增加監管支持並加快關鍵市場新 PDGFR 抑制劑的核准
      • 製藥巨頭之間的策略聯盟促進PDGFR抑制劑的廣泛分佈
      • 藥物輸送系統的技術進步可提高 PDGFR 抑制劑的療效和患者依從性
    • 抑制因素
      • 醫護人員對 PDGFR 抑制劑的益處和用途缺乏認知
      • 分銷挑戰限制了 PDGFR 抑制劑在新興市場的可用性
    • 機會
      • 合作推進 PDGFR 抑制劑開發的生物製藥進展
      • 在全球擴大 PDGFR 抑制劑的臨床試驗，以滿足未滿足的醫療需求
      • 加速罕見疾病核准的監管獎勵
    • 任務
      • 來自替代療法的競爭壓力降低了 PDGFR 抑制劑的市場佔有率
      • 智慧財產權和專利糾紛阻礙PDGFR抑制劑的市場動態
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境的

第6章 PDGFR 抑制劑市場待遇：依適應症分類

  • 胃腸道基質腫瘤
  • 神經膠母細胞瘤
  • 白血病

第7章 PDGFR 抑制劑市場：依藥物類型

  • 聯合治療
  • 單一療法

第8章 PDGFR 抑制劑市場：依管理方法分類

  • 靜脈
  • 口服

第 9 章 PDGFR 抑制劑市場：依最終用戶分類

  • 醫院
  • 研究/學術機構
  • 專科診所

第10章美洲PDGFR抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太PDGFR抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲PDGFR抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Deciphera Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Incyte Corporation
  • MedChemExpress
  • Merck KGaA
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • R&D Systems, Inc.
  • Santa Cruz Biotechnology, Inc.
  • TargetMol Chemicals Inc.
  • Tocris Bioscience
  • Zai Lab Limited
Product Code: MRR-9A6A6F297DE6

The PDGFR Inhibitor Market was valued at USD 3.21 billion in 2023, expected to reach USD 3.43 billion in 2024, and is projected to grow at a CAGR of 5.21%, to USD 4.59 billion by 2030.

The scope and definition of PDGFR (Platelet-Derived Growth Factor Receptor) inhibitors revolve around targeting the PDGFR signaling pathway, which is crucial for cell proliferation, survival, and migration, thus providing treatment avenues for diseases like cancer and fibrotic conditions. These inhibitors are necessary due to their therapeutic potential in managing malignancies such as glioblastomas, prostate cancer, and rarer conditions like dermatofibrosarcoma protuberans. By impeding the signaling pathways, these drugs curb tumor growth and metastasis, which are primary applications. The end-use scope of PDGFR inhibitors predominantly spans the pharmaceutical and biotechnology sectors, alongside hospitals and research institutions that employ these drugs in clinical trials and therapeutic settings.

KEY MARKET STATISTICS
Base Year [2023] USD 3.21 billion
Estimated Year [2024] USD 3.43 billion
Forecast Year [2030] USD 4.59 billion
CAGR (%) 5.21%

Market insights indicate that the growth is primarily driven by the increasing prevalence of oncological disorders, significant R&D investments, and the urgent need for novel cancer therapies. Technological advancements and personalized medicine trends further catalyze market expansion. Emerging opportunities lie within the development of combination therapies and targeting resistant tumor genomics. Companies can capitalize on these by investing in collaborative research and strategic alliances with biotech firms. However, stringent regulatory approvals, high development costs, and potential side effects pose significant challenges, restricting market growth. There is also the competitive pressure from alternative therapies and resistance development in tumors, which necessitates continuous innovation.

For fostering innovation and research, exploring molecular mechanisms and novel biomarkers for better efficacy and safety profiles of PDGFR inhibitors is paramount. Market growth insight reveals a focus on developing less toxic, more selective inhibitors with enhanced bioavailability. The nature of the PDGFR inhibitor market is competitive, with key players continuously seeking edges through strategic mergers, acquisitions, and collaborations to boost their pipelines. With these dynamics, the PDGFR inhibitor market remains poised for steady growth, offering significant opportunities for companies that skillfully navigate the market's complexities and capitalize on emerging trends and unmet medical needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PDGFR Inhibitor Market

The PDGFR Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding clinical applications owing to substantial research and development in PDGFR inhibitor uses
    • Enhanced regulatory support and fast-track approvals for new PDGFR inhibiting drugs in key markets
    • Strategic collaborations between pharmaceutical giants aiding in extensive distribution of PDGFR inhibitors
    • Technological advancements in drug delivery systems improving the efficacy and patient compliance of PDGFR inhibitors
  • Market Restraints
    • Lack of awareness among healthcare professionals about the benefits and uses of PDGFR inhibitors
    • Limited availability of PDGFR inhibitors in emerging markets due to distribution challenges
  • Market Opportunities
    • Collaborative partnerships driving biopharmaceutical advancements in PDGFR inhibitor development
    • Expanding global clinical trials for PDGFR inhibitors to address unmet medical needs
    • Regulatory incentives for accelerated PDGFR inhibitor approvals in rare diseases
  • Market Challenges
    • Competitive pressure from alternative therapies reducing market share for PDGFR inhibitors
    • Intellectual property and patent disputes hindering market dynamics for PDGFR inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the PDGFR Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PDGFR Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PDGFR Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PDGFR Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PDGFR Inhibitor Market

A detailed market share analysis in the PDGFR Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PDGFR Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PDGFR Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PDGFR Inhibitor Market

A strategic analysis of the PDGFR Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PDGFR Inhibitor Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline, Incyte Corporation, MedChemExpress, Merck KGaA, Novartis Pharmaceuticals Corporation, Pfizer Inc., R&D Systems, Inc., Santa Cruz Biotechnology, Inc., TargetMol Chemicals Inc., Tocris Bioscience, and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the PDGFR Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Indication, market is studied across Gastrointestinal Stromal Tumors, Glioblastoma, and Leukemia.
  • Based on Drug Type, market is studied across Combination Therapy and Monotherapy.
  • Based on Mode Of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding clinical applications owing to substantial research and development in PDGFR inhibitor uses
      • 5.1.1.2. Enhanced regulatory support and fast-track approvals for new PDGFR inhibiting drugs in key markets
      • 5.1.1.3. Strategic collaborations between pharmaceutical giants aiding in extensive distribution of PDGFR inhibitors
      • 5.1.1.4. Technological advancements in drug delivery systems improving the efficacy and patient compliance of PDGFR inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness among healthcare professionals about the benefits and uses of PDGFR inhibitors
      • 5.1.2.2. Limited availability of PDGFR inhibitors in emerging markets due to distribution challenges
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative partnerships driving biopharmaceutical advancements in PDGFR inhibitor development
      • 5.1.3.2. Expanding global clinical trials for PDGFR inhibitors to address unmet medical needs
      • 5.1.3.3. Regulatory incentives for accelerated PDGFR inhibitor approvals in rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Competitive pressure from alternative therapies reducing market share for PDGFR inhibitors
      • 5.1.4.2. Intellectual property and patent disputes hindering market dynamics for PDGFR inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PDGFR Inhibitor Market, by Therapeutic Indication

  • 6.1. Introduction
  • 6.2. Gastrointestinal Stromal Tumors
  • 6.3. Glioblastoma
  • 6.4. Leukemia

7. PDGFR Inhibitor Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Combination Therapy
  • 7.3. Monotherapy

8. PDGFR Inhibitor Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. PDGFR Inhibitor Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research & Academic Institutes
  • 9.4. Specialty Clinics

10. Americas PDGFR Inhibitor Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific PDGFR Inhibitor Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa PDGFR Inhibitor Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Blueprint Medicines Corporation
  • 3. Boehringer Ingelheim International GmbH
  • 4. Bristol Myers Squibb
  • 5. Deciphera Pharmaceuticals, Inc.
  • 6. Eli Lilly and Company
  • 7. Exelixis, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline
  • 11. Incyte Corporation
  • 12. MedChemExpress
  • 13. Merck KGaA
  • 14. Novartis Pharmaceuticals Corporation
  • 15. Pfizer Inc.
  • 16. R&D Systems, Inc.
  • 17. Santa Cruz Biotechnology, Inc.
  • 18. TargetMol Chemicals Inc.
  • 19. Tocris Bioscience
  • 20. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. PDGFR INHIBITOR MARKET RESEARCH PROCESS
  • FIGURE 2. PDGFR INHIBITOR MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PDGFR INHIBITOR MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PDGFR INHIBITOR MARKET DYNAMICS
  • TABLE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023